Completed PHASE1 INTERVENTIONAL NCT01479361

Antiretroviral Drug Interaction Study in Volunteers With HIV

The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers

Sponsor: National Institutes of Health Clinical Center (CC)

Interventions Atovaquone 1500 mg twice daily Atovaquone 750 mg twice daily

Updated 7 times since 2017 Last updated: Jul 3, 2018 Started: Oct 31, 2011 Primary completion: Feb 20, 2014 Completion: Feb 20, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV and PCP, this trial is completed. The trial is conducted by National Institutes of Health Clinical Center (CC) and has accumulated 7 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institutes of Health Clinical Center (CC)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States